SCHEMBL6283549

SCHEMBL6283549

Nc1ccc(NC(=O)Nc2ncc(Br)s2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.56
RAB9A P51151 3/20 0.56
FBP1 P09467 9/20 0.54
SMN1; SMN2 Q16637 3/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
NFKB1 P19838 1/20 0.51
NFKB2 Q00653 1/20 0.51
RELA Q04206 1/20 0.51
CCNE1 P24864 3/20 0.48
CDK2 P24941 3/20 0.48
CDK5 Q00535 3/20 0.48
CNR1 P21554 1/20 0.47
NPC1 O15118 1/20 0.46
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.46
HTT P42858 1/20 0.46
MAPK10 P53779 1/20 0.46
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6287994 0.87 SMN1; SMN2 (0.52) MAPTRAB9AFBP1SMN1; SMN2MEN1
SCHEMBL6285641 0.85 RAB9A (0.70) MAPTRAB9AFBP1SMN1; SMN2MEN1
SCHEMBL4715713 0.85 CDK2 (0.63) MAPTRAB9AFBP1SMN1; SMN2MEN1
SCHEMBL6285988 0.84 MDM2 (0.58) MAPTRAB9AFBP1SMN1; SMN2MEN1
SCHEMBL6282741 0.83 CA12 (0.61) FBP1MEN1KMT2ACA12CA1
SCHEMBL6285829 0.83 FBP1 (0.65) MAPTRAB9AFBP1SMN1; SMN2MEN1
SCHEMBL6278432 0.82 SMN1; SMN2 (0.60) MAPTRAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL6282569 0.81 MEN1 (0.60) MAPTRAB9AFBP1SMN1; SMN2MEN1
SCHEMBL6371309 0.80 MAPT (0.62) MAPTRAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL6281782 0.79 CDK2 (0.76) MAPTRAB9ASMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PEVARELLO PAOLO (IT) 2004-08-12 US claimed
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN SPA (IT) 2003-10-02 US claimed
US-6863647-B2 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN S.P.A. (IT) 2005-03-08 US disclosed
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PEVARELLO PAOLO (IT) 2004-08-12 US disclosed
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN SPA (IT) 2003-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents UCK2, ULK3, CDK2 MAPT 3745/4885RAB9A 2674/4885FBP1 2931/4885
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents UCK2, ULK3, CDK2 MAPT 3745/4885RAB9A 2674/4885FBP1 2931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.